



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, D.C. 20231
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/896,052	06/29/2001	Frank J. Bunick	MCP-281	9476

27777 7590 09/04/2002
AUDLEY A. CIAMPORCERO JR.
JOHNSON & JOHNSON
ONE JOHNSON & JOHNSON PLAZA
NEW BRUNSWICK, NJ 08933-7003

EXAMINER

OH, SIMON J

ART UNIT PAPER NUMBER

1615

DATE MAILED: 09/04/2002

Please find below and/or attached an Office communication concerning this application or proceeding.

Office Action Summary

Application No.

09/896,052

Applicant(s)

BUNICK ET AL.

Examiner

Simon J. Oh

Art Unit

1615

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133).
- Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) ☐ Responsive to communication(s) filed on ____.
- 2a) ☐ This action is **FINAL**. 2b) ☒ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) ☒ Claim(s) 1-16 is/are pending in the application.
- 4a) Of the above claim(s) ____ is/are withdrawn from consideration.
- 5) ☐ Claim(s) ____ is/are allowed.
- 6) ☒ Claim(s) 1-16 is/are rejected.
- 7) ☐ Claim(s) ____ is/are objected to.
- 8) ☐ Claim(s) ____ are subject to restriction and/or election requirement.

Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on ____ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.
- Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
- 11) ☐ The proposed drawing correction filed on ____ is: a) ☐ approved b) ☐ disapproved by the Examiner.
- If approved, corrected drawings are required in reply to this Office action.
- 12) ☐ The oath or declaration is objected to by the Examiner.

Priority under 35 U.S.C. §§ 119 and 120

- 13) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All b) ☐ Some * c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
2. ☐ Certified copies of the priority documents have been received in Application No. ____.
3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).
- * See the attached detailed Office action for a list of the certified copies not received.
- 14) ☐ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application).
- a) ☐ The translation of the foreign language provisional application has been received.
- 15) ☐ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121.

Attachment(s)

- 1) ☒ Notice of References Cited (PTO-892)
- 2) ☐ Notice of Draftsperson's Patent Drawing Review (PTO-948)
- 3) ☐ Information Disclosure Statement(s) (PTO-1449) Paper No(s) ____.
- 4) ☐ Interview Summary (PTO-413) Paper No(s). ____.
- 5) ☐ Notice of Informal Patent Application (PTO-152)
- 6) ☐ Other: _____.

DETAILED ACTION

Response to Arguments

Applicant's arguments with respect to Claims 1-16 have been considered but are moot in view of the new ground(s) of rejection.

Claim Rejections - 35 USC § 103

The text of those sections of Title 35, U.S. Code not included in this action can be found in a prior Office action.

Claims 1-4 and 6-16 are rejected under 35 U.S.C. 103(a) as being unpatentable over Mehta.

Claim 5 is rejected under 35 U.S.C. 103(a) as being unpatentable over Mehta in view of Lee.

Mehta teaches a chewable, taste-masked pharmaceutical dosage form, preferably in the form of a tablet (See Column 1, Lines 6-28). The components of this dosage form comprise taste-masked microcapsules, which may then be prepared as chewable tablets. The microcapsules themselves comprise a polymeric coating that masks the taste of the active ingredient, and a pharmaceutical core (See Column 4, Lines 4-12; and Examples 1 and 2). Acetaminophen and ibuprofen are listed among suitable drugs for use in the reference (See Column 7, Lines 31-48; and Claims 11 and 12). Diluents acceptable for use in the microcapsule core include gelatin (See Column 7, Line 59 to Column 8, Line 12). In the given examples, the preferred size of the uncoated acetaminophen particles used lies in the range of 150 to 300

Art Unit: 1615

microns (See Column 10, Lines 45-47); and a rationale for such a limitation is given as well (See Column 2, Lines 18-35). The reference also teaches that the coated pharmaceutical cores may then be encapsulated in a hard gelatin capsule or further coated with candy (See Column 9, Lines 35-40). In regards to the limitation of the weight ratio of the drug particles to the outer shell, the examiner sees no criticality in such a feature. The examiner is of the opinion that the inventions of the prior art perform their intended use, that is, the taste-masking and delivery of active substances, without explicitly possessing such characteristics. Similarly, the examiner is of the opinion that the brittleness limitation presented in Claim 6 is also not critical for the same reason.

Mehta does not teach the use of a pectin-based core.

Lee teaches a chewable pharmaceutical dosage form comprising of a core containing an active ingredient, and an outer layer (See Figure 2). The core may be in the form of a jelly, with the base of the jelly selected from a group that includes pectin (See Column 2, Lines 29-33). In addition, gelatin may be used in either the core or outer layer to maintain hardness and extension property in the dosage form (See Column 2, Lines 59-61). The outer layer may take a variety of forms, including hard candy (See Column 2, Lines 34-42). Acetaminophen is listed as a possible active ingredient in core (See Column 2, Lines 9-18).

It would be obvious to one of ordinary skill in the art to combine the teachings of Mehta and Lee into the objects of the instant application. As stated in *In re Kerkhoven*, 205 USPQ 1069, 1072 (CCPA- 1980), "It is prima facie obvious to combine two compositions, each of which is taught by the prior art to be useful for the same purpose, in order to form a third composition which is to be used for the very same purpose." As this court explained in *Crockett*, 126 USPQ 186, 188 (CCPA- 1960), the idea of combining them flows logically from their

Art Unit: 1615

having been individually taught in the prior art. Both Mehta and Lee teach a chewable dosage form, comprising of a brittle outer shell and a soft core, which masks the taste of the bitter active ingredients such as acetaminophen and ibuprofen, for the purpose of increasing the likelihood of patient compliance.

Applicant's arguments filed July 1, 2002, have been fully considered but they are not persuasive. Claims 1, 15, and 16 of the instant application contain limitations drawn to active agent particles having an average size greater than about 50 microns. Mehta contains a disclosure of uncoated acetaminophen particles ranging in size from 150 to 300 microns. It is the position of the examiner that this reference was of particular relevance because the disclosed range falls within a narrowed particle size range made in the applicant's own specification, from about 150 to about 500 microns (Page 7, Paragraph [0016] of the instant specification). In its present form, the claims of the instant application are drawn to pharmaceutical compositions. No limitations presently exist in the claims regarding the location of the release of the active agent in the gastrointestinal tract, nor to methods of taste- or texture-masking. The prior art therefore reads on the claims, and the claimed invention, as a whole, is *prima facie* obvious.

Correspondence

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Simon J. Oh whose telephone number is (703) 305-3265. The examiner can normally be reached on M-F 8:30 am to 5:00 pm.


Art Unit: 1615

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Thurman K Page can be reached on (703) 308-2927. The fax phone numbers for the organization where this application or proceeding is assigned are (703) 305-3014 for regular communications and (703) 305-3014 for After Final communications.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is (703) 308-1234.

Simon J. Oh
Patent Examiner
AU 1615

sjo
August 30, 2002


THURMAN K. PAGE
SUPERVISORY PATENT EXAMINER
TECHNOLOGY CENTER 1600